Abstract:Abstract Chromosomal alterations that occur frequently in cancers confer selective advantages for tumor progression by deleting tumor-suppressing genes or amplifying oncogenic drivers. However, the collateral effect of these, i.e., deletion of essential genes or upregulation of metabolic regulators, exposes cancers to biological pressures by suppressing essential metabolic pathways. Cancer cells rely on paralogous metabolic pathways to compensate for this loss of function, which in turn opens the door to exploit metabolic vulnerabilities arising as a direct consequence of chromosomal alterations. These pathways are collateral lethal (CL) targets and offer a unique precision medicine approach for metabolic therapeutics. We have developed an integrated machine learning and systems biology platform, collateral lethal gene identification via metabolic fluxes (CLIM) to identify metabolic targets across multiple cancers. Results: In ovarian cancers with 19p13.3 deletion, a loss of Complex III subunit-encoding gene UQCR11 occurs, leading to suppressed electron transport chain (ETC) activity. CLIM predicted that MTHFD2 acts noncanonically to oxidize NADH to NAD+ to compensate for reduced NAD+ recycling via the ETC. We demonstrate selective death of ETC deficient ovarian cancers by targeting MTHFD2 and provide mechanistic validation of oxidative MTHFD2 flux. We observed significant shrinkage of ovarian tumors with ETC deficiency upon MTHFD2 knockdown in mouse models. In triple negative breast cancers (TNBC), we discovered a chromosomal amplification leading to reprogramming of the serine biosynthesis pathway. CLIM predicts a target in the tryptophan metabolism. Methods: Patients are stratified using machine learning to identify tumors with distinct chromosomal alterations. Multiobjective metabolic flux analysis is employed to predict CL pathways in curated genome-scale metabolic models. Validation of metabolic rewiring predicted by CLIM were examined using 3-2H-glucose, 4-2H-glucose and 2,3,3-2H-serine to probe the one carbon metabolism. Oxidative MTHFD2 flux was quantified using innovative combinatorial tracer study with 2H-formate and 4-2H-glucose. We utilized gain- and loss-of-function assays in multiple cell-lines to show utility of the predicted CL targets in TNBCs with chromosomal amplifications. Conclusion: Our integrated platform successfully identifies CL gene pairs to decipher novel metabolic targets specific to chromosomal alterations across many cancer types. Importantly, targets identified by CLIM are based on quantitative flux analysis. This approach reveals functional connection between CL pairs, thereby providing a mechanistic understanding of emerging lethality. This is critical in developing therapeutic interventions that selectively target cancer cells, with minimal off-target or side effects. Citation Format: Abhinav Achreja, Jin Heon Jeon, Mark Slayton, Tao Yu, Olamide Animasahun, Minal Nenwani, Fulei Wuchu, Anjali Mittal, Xiongbin Lu, Sofia D. Merajver, Deepak Nagrath. Identification of collateral lethal targets in cancers using integrated machine learning and flux analysis platform for personalized metabolic therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6037.

Abstract 1204: Design of Phenotype-Driven Flux Analysis Approach for Personalized Metabolic Models of Cancer Patients

Abstract 2072: Computational modeling of metabolic variations in tumor microenvironment

Abstract 2349: A phenotypic model for cancer metabolism

Abstract 3372: Constraints-based Metabolic Flux Analysis Approach Links Tumor Stage to Metabolic Adaptations and Survival in Cancer Cells

Abstract 236: Genomic Loss in Cancers Enable Discovery of Metabolic Targets for Precision Cancer Therapy Via Multiobjective Flux Analysis and Machine Learning

Abstract 2047: Flux estimation analysis systematically characterizes the metabolic shifts of the central metabolism pathway in human cancer

Abstract 1892: Integrated energetics and flux analysis reveals differential metabolic reprogramming in highly and less invasive cancer cells.

Computational modeling of cancer cell metabolism along the catabolic-anabolic axes

Abstract 1789: Machine learning-based method to analyze metabolic fluxes of patient tumors

Identifying Personalized Metabolic Signatures in Breast Cancer

Personalized Metabolic Analysis of Diseases

Abstract 6037: Identification of Collateral Lethal Targets in Cancers Using Integrated Machine Learning and Flux Analysis Platform for Personalized Metabolic Therapy

Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux

Abstract IA016: Metabolic reprogramming and cancer progression in patients

Identification of Cancer–associated Metabolic Vulnerabilities by Modeling Multi-Objective Optimality in Metabolism

Pan-Cancer, Genome-Scale Metabolic Network Analysis of over 10,000 Patients Elucidates Relationship between Metabolism and Survival

Abstract 469: A multi-scale analysis and visualization platform for cancer data - deriving tumor microenvironment behavior from pathology and transcriptomics

MMP3C: an in-silico framework to depict cancer metabolic plasticity using gene expression profiles

Tmet-27. Machine Learning-Based Identification Of Metabolic Fluxes In Patient Brain Tumors

Abstract A023: Integrating mathematical modeling and in vitro experiments to measure ecological interactions in cancer

Modeling of Tumor Growth with Input from Patient-Specific Metabolomic Data